Epigenomics Ag Stock Current Ratio
| EPGNYDelisted Stock | USD 9.56 0.00 0.00% |
Epigenomics AG fundamentals help investors to digest information that contributes to Epigenomics' financial success or failures. It also enables traders to predict the movement of Epigenomics OTC Stock. The fundamental analysis module provides a way to measure Epigenomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Epigenomics otc stock.
Epigenomics |
Epigenomics AG OTC Stock Current Ratio Analysis
Epigenomics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Epigenomics Current Ratio | 5.84 X |
Most of Epigenomics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Epigenomics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Epigenomics AG has a Current Ratio of 5.84 times. This is 100.69% higher than that of the Healthcare sector and 30.94% higher than that of the Diagnostics & Research industry. The current ratio for all United States stocks is 170.37% lower than that of the firm.
Epigenomics Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Epigenomics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Epigenomics could also be used in its relative valuation, which is a method of valuing Epigenomics by comparing valuation metrics of similar companies.Epigenomics is currently under evaluation in current ratio category among its peers.
Epigenomics Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (15.90) % | |||
| Current Valuation | (9.71 M) | |||
| Shares Outstanding | 817.87 K | |||
| Price To Earning | (10.48) X | |||
| Price To Book | 0.53 X | |||
| Price To Sales | 13.79 X | |||
| Revenue | 6.2 M | |||
| Gross Profit | 6.07 M | |||
| EBITDA | (1.94 M) | |||
| Net Income | (2.43 M) | |||
| Cash And Equivalents | 18.04 M | |||
| Cash Per Share | 5.51 X | |||
| Total Debt | 1.01 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 5.84 X | |||
| Book Value Per Share | 17.04 X | |||
| Cash Flow From Operations | (4.15 M) | |||
| Earnings Per Share | (1.49) X | |||
| Number Of Employees | 36 | |||
| Beta | 1.21 | |||
| Market Capitalization | 6.44 M | |||
| Total Asset | 24.66 M | |||
| Retained Earnings | (69.31 M) | |||
| Working Capital | 5.54 M | |||
| Current Asset | 10.99 M | |||
| Current Liabilities | 5.46 M | |||
| Z Score | 0.8 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 24.66 M |
About Epigenomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Epigenomics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Epigenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Epigenomics AG based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Epigenomics OTC Stock
If you are still planning to invest in Epigenomics AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epigenomics' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |